Preliminary Studies of the Impact of CXCL12 on the Foreign Body Reaction to Pancreatic Islets Microencapsulated in Alginate in Nonhuman Primates by Sremac, Marinko et al.
  
 University of Groningen
Preliminary Studies of the Impact of CXCL12 on the Foreign Body Reaction to Pancreatic
Islets Microencapsulated in Alginate in Nonhuman Primates
Sremac, Marinko; Lei, Ji; Penson, Madeline F E; Schuetz, Christian; Lakey, Jonathan R T;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Sremac, M., Lei, J., Penson, M. F. E., Schuetz, C., Lakey, J. R. T., Papas, K. K., ... Hering, B. (2019).
Preliminary Studies of the Impact of CXCL12 on the Foreign Body Reaction to Pancreatic Islets
Microencapsulated in Alginate in Nonhuman Primates. Transplantation direct, 5(5), [e447].
https://doi.org/10.1097/TXD.0000000000000890
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





















































Transplantation DIRECT   ■   2019 www.transplantationdirect.com 1
J.M. performed the transplantation of microbeads and contributed to the design 
of the study. M.C.P. directed the study and provided substantial contributions 
to the conception and design of the work, participated in drafting the work and 
revised it critically for important intellectual content, participated in the writing and 
editing of the manuscript, and was responsible for the final approval of the version 
to be published.
M.S. and J.L. contributed equally to this manuscript.
M.C.P. is the scientific founder of ViCapsys. J.M. was a scientific consultant to 
ViCapsys.
The present work was supported by the JDRF (grant 2-SRA-2014-290-Q-R) 
and the VIC Innovation Fund.
Supplemental digital content (SDC) is available for this article. Direct URL citations 
appear in the printed text, and links to the digital files are provided in the HTML 
text of this article on the journal’s Web site (www.transplantationdirect.com).
Correspondence: Dr Mark C. Poznansky, MD, PhD, Director, Vaccine and 
Immunotherapy Center, Massachusetts General Hospital, 149 13th St, 
Charlestown, MA 02129. (mpoznansky@partners.org).
Copyright © 2019 The Author(s). Transplantation Direct. Published by Wolters 
Kluwer Health, Inc. This is an open-access article distributed under the terms of 
the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible to download and share the work provided 
it is properly cited. The work cannot be changed in any way or used commercially 
without permission from the journal.
ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000890
Received 8 February 2019. Accepted 4 March 2019.
1 Department of Infectious Diseases,  Vaccine and Immunotherapy Center, 
Massachusetts General Hospital, Boston, MA.
2 Division of Transplant Surgery, The Pancreas/Islet Transplant Program, 
Massachusetts General Hospital, Boston, MA.
3 Clinical Islet Program, Surgery School of Medicine,  University of California 
Irvine, Irvine, CA.
4 Department of Surgery, Institute for Cellular Transplantation, University of 
Arizona, Tucson, AZ.
5 ViCapsys, Inc., Athens, GA.
6 Department of Pathology and Medical Biology, University of Groningen, 
Groningen, The Netherlands.
7 Department of Surgery, University of Minnesota, Minneapolis, MN.
M.S. performed the experiments, analyzed the data, participated in writing and 
editing of the manuscript, and provided substantial contributions to the conception 
and design of the work, acquisition, analysis, and interpretation of data. J.L. 
performed pre- and postsurgery clinical care of NHPs, donor pancreas recovery 
surgery, and isolated NHP islets, performed transplantation of microbeads, 
and  designed the NHP research protocol and surgical procedure. M.F.E.P. 
performed experiments and analyzed the data. C.S. performed pretransplant and 
posttransplant care of the animals. J.R.T.L. provided the consultation on study 
design and encapsulation protocols. K.K.P. provided the consultation in designing 
the study. P.S.V. provided the consultation in the analysis of microbeads. P.d.V. 
and B.H. provided the consultation in designing the study. T.B. participated in 
project management, designed the study, and edited the article, contributed to 
the design of experiments, interpretation of results, and writing of the manuscript. 
Preliminary Studies of the Impact of CXCL12 on 
the Foreign Body Reaction to Pancreatic Islets 
Microencapsulated in Alginate in Nonhuman 
Primates
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Pancreas and Islet Transplantation
Background. We previously demonstrated that the incorporation of the chemokine CXCL12 into alginate microbeads 
supported long-term survival of microencapsulated auto-, allo-, and xenogeneic islets in murine models of diabetes with-
out systemic immune suppression. The purpose of this study was to test whether CXCL12 could abrogate foreign body 
responses (FBRs) against alginate microbeads which were empty or contained autologous islets in healthy nonhuman 
primates (NHPs; n = 4). Methods. Two NHPs received intraperitoneal implants of 400 000 alginate microbeads with or 
without CXCL12, and postimplantation immunological and histopathological changes were evaluated up to 6 months post-
implantation. A similar evaluation of autologous islets in CXCL12-containing alginate microbeads was performed in NHPs 
(n = 2). Results. CXCL12-containing alginate microbeads were associated with a markedly reduced FBR to microbeads. 
Host responses to microbead implants were minimal, as assessed by clinical observations, blood counts, and chemistry. 
Evaluation of encapsulated islets was limited by the development of necrotizing pancreatitis after hemipancreatectomy in 1 
NHP. A limited number of functioning islets were detectable at 6 months posttransplantation in the second NHP. In general, 
empty microbeads or islet-containing beads were found to be evenly distributed through the intraperitoneal cavity and did 
not accumulate in the Pouch of Douglas. Conclusions. Inclusion of CXCL12 in alginate microbeads minimized localized 
FBR. The NHP autologous islet implant model had limited utility for excluding inflammatory/immune responses to implanted 
islets because of the complexity of pancreatic surgery (hemipancreatectomy) before transplantation and the need to micro-
encapsulate and transplant encapsulated autologous islets immediately after pancreatectomy and islet isolation.
(Transplantation Direct 2019;5:e447; doi: 10.1097/TXD.0000000000000890. Published online 15 April, 2019.)
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While insulin replacement therapy has made a signifi-cant contribution toward prolonging and enhancing 
the life of the people with type 1 diabetes, it is not yet an opti-
mal treatment, as it cannot dynamically regulate blood sugar 
levels with the precision of islets. Over the last 30 years, allo-
geneic islet transplantation has become a firmly established 
treatment modality that may soon receive regulatory approval 
for clinical use.1 Nevertheless, its potential impact is limited 
by the scarcity of suitable deceased-donor islets and the need 
to provide recipients lifelong systemic immune suppression 
therapy to prevent islet rejection.
These limitations have led investigators to explore the use 
of alternative islet replacement sources like porcine islets, 
which do not have supply limitations, and to replace sys-
temic immune suppression with localized immune protection. 
One embodiment of this approach is enclosure of the islet 
within microspheres of a biocompatible polymer or polymers. 
Alginate, a natural polymer derived from brown seaweed, has 
emerged as a leading candidate for this approach, as it can 
be readily formed into such microspheres, its biocompatibility 
has been tested in a range of animal models,2-6 and it has been 
used for implantation or injection in several approved or clini-
cal stage therapeutics.7-10 Numerous studies have guided inves-
tigators toward utilization of high-purity forms of alginate as 
a means of minimizing unwanted foreign body reactions and 
immune responses11-15 and to capsule designs incorporating 
polylysine or polyornithine shells that can exclude the passage 
of larger unwanted immune proteins.16,17
We have previously explored the incorporation of a 
recombinant form of the human chemokine CXCL12 alpha 
(CXCL12) into alginate microbeads as a means of providing 
a long-term, site-specific, immunoprotective, and prosurvival 
environment for both allogeneic and xenogeneic islets. At 
local concentrations of 1  μg/mL, CXCL12 has been shown 
to selectively repel effector T cells while continuing to recruit 
and retain immune-suppressive regulatory T cells to an ana-
tomic site in models of transplantation and cancer.18,19 In an 
immunocompetent diabetic mouse model, implantation of 
simple alginate microbeads containing allogeneic and xenoge-
neic islets and CXCL12 with a starting concentration of 1 μg/
mL extended euglycemia to >300 days compared with micro-
beads without or with lower concentrations of CXCL12.5
In addition to its immunomodulatory effects, CXCL12 
has also been shown to play a role in reducing inflammatory 
responses at sites of injury,20,21 to promote healing through the 
recruitment of endothelial progenitor cells,22-24 and to act as 
a prosurvival signal for beta cells.25 CXCL12 is also likely to 
attract stem cells that further modify the environment around 
the microbead toward healing26,27 and immune tolerance.28 
Thus, CXCL12 has “multimodal” potential to extended 
survival and function for implanted islets. In this context, 
we use simple microbeads of ultrapure alginate, which not 
only provide a supportive and protective matrix for islets but 
also enable prolonged release of CXCL12 to enhance islet 
survival while dampening inflammatory responses and pro-
moting immune tolerance of the islet-containing microbeads. 
In this study, we set out to examine in a stepwise manner 
whether data in mice could be reproduced in nonhuman pri-
mates (NHPs)—commencing with a study of intraperitoneal 
(IP)  implantation of alginate microbeads with and without 
CXCL12 and subsequently alginate microbeads containing 
autologous islets with CXCL12.
Results from these preliminary studies suggest that in 
NHPs, implants of CXCL12-containing microbeads were 
well tolerated and that the chemokine modulates host innate 
immune responses toward the alginate microbeads. However, 
we found that the use of an autologous islet implant model 
to isolate immune effects against the alginate microbead was 
undermined by the immune activating effects of the surgery 
itself, the inability to culture autologous islets over prolonged 
periods of time to reduce antigenicity from dying islets, and 
the development of significant postsurgical pancreatitis in 1 
animal. Overall, these studies provide the support for contin-
ued testing of the use of CXCL12 in alginate microbeads to 
encapsulate allogeneic and xenogeneic islets and to identify 
key parameters that can maximize the success of follow-on 
transplantation studies. In addition, our study highlights the 
complexities and potential confounding factors generated in 
the autologous islet transplant model in NHPs.
MATERIALS AND METHODS
Ultrapurified Alginate and Its Characterization
We utilized ultrapure low-viscosity, high-mannuronic acid 
(LVM) alginate produced under current Good Manufacturing 
Practice conditions (FMC Biopolymers/NovaMatrix, Lot #BP-
1410–28). A number of key characteristics of the alginate 
reported in the certificate of analysis, including purity, endo-
toxin levels, mannuronic acid concentration, and  apparent 
and dynamic viscosity, were verified by our laboratory or by 
other investigators. We evaluated the level of endotoxins in 
both unfiltered and sterile-filtered (0.8/0.2-μm filter) alginate 
using the Endosafe PTS (Charles River Laboratories) detection 
system in accordance with a standard operating procedure 
derived from the manufacturer’s instructions. Further analyses 
of the immunoactivating potential of the alginate were per-
formed using established in vitro HEK-Blue and THP-1 cell 
activation assays and quantitative ELISAs to identify the con-
centrations of lipopolysaccharides, peptidoglycan, lipoteichoic 
acid, and flagellin within the alginate. These assays were per-
formed in accordance with published procedures.29
Characterization of Recombinant Human CXCL12
We used recombinant human CXCL12 reconstituted in 
sterile normal saline at a concentration of 1 μg/mL throughout 
this study (Peprotech, Lot #300-28A). The purity and identity 
of the protein was confirmed by 21st Century Biochemicals 
(Marlborough, MA) utilizing high-performance liquid chro-
matography and liquid chromatography–mass spectrom-
etry. Endotoxin contamination of this bacterially expressed 
chemokine was evaluated using the Endosafe PTS assay.
Production of Alginate Encapsulation Solution
Ultrapure low-viscosity, high-mannuronic acid alginate was 
used to produce microbeads with and without CXCL12 and 
with CXCL12 and autologous primate islets. A 1.6%-weight 
per volume sodium alginate solution was prepared by mix-
ing the alginate with an endotoxin-free 300-mOsmol sodium 
chloride (NaCl) solution (Sigma, Cat #5150-1L) and passed 
through a 0.8/0.2-μm sterile syringe filter (Pall Life Sciences, 
Cat #4658). For preparations that incorporated CXCL12, 
the chemokine was dissolved in 300 mOsmol NaCl and 
mixed with alginate to produce a resultant solution with a 
chemokine concentration of 1 μg/mL weight to volume of 
alginate solution.
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NHP Pancreatic Islet Isolation
Donor islets were isolated from pancreatic tissue follow-
ing a hemipancreatectomy procedure on the donor/recipient 
NHP. The protocol of islet isolation was based on a modi-
fied human islet isolation method (Materials and Methods S1, 
SDC, http://links.lww.com/TXD/A205).
Production and Characterization of Alginate 
Microbeads
The B-395 Pro Encapsulator (Buchi Corporation, New 
Castle, DE) was used to produce all microbeads for this study. 
We produced the empty microbeads and the first autologous 
islet-containing microbeads using a vibrational encapsulation 
technique with a 200- or 300-μm nozzle.30,31 For the second 
set of autologous islet microbeads, an airflow technique with a 
400-μm air-dripping nozzle was used (Materials and Methods 
S2, SDC, http://links.lww.com/TXD/A205).
NHPs and Surgical Procedure for Microbead 
Implantation and Partial Pancreatectomy
NHPs (male 1- to 2-year-old Mauritian origin cynomolgus 
monkeys) were obtained from Charles River Laboratories 
(Houston, TX). IP implantation of empty microbeads was 
performed using a minimally invasive technique with healthy 
male cynomolgus monkeys (Macaca fascicularis), 2 to 3 years 
old, 4–5 kg. One NHP received microbeads without CXCL12 
(−), and a second NHP received microbeads with CXCL12 (+). 
Surgeons and pathologists were blinded to the CXCL12 con-
tent of the implant. All procedures and the protocol followed 
were approved by the Center for Comparative Medicine at 
Massachusetts General Hospital. Surgical evaluation of NHPs 
peritoneum and explant of free and embedded microbeads 
were done at 1, 3, and 6 months after microbead implanta-
tion (Materials and Methods S3, SDC, http://links.lww.com/
TXD/A205).
NHP Plasma, Serum Collection, and PBMC Isolation
Blood samples were taken from the NHPs before surgery 
(days −7 and 0) and posttransplantation in weeks 1–4, 13, 
and 26. Plasma and intra-abdominal aspirate samples were 
analyzed for the levels of 14 different cytokines and CXCL12. 
Peripheral blood mononuclear cells (PBMCs) from the blood 
samples were analyzed by flow cytometry (Materials and 
Methods S4, SDC, http://links.lww.com/TXD/A205).
Islet Functional Studies
Static glucose stimulation index assays were performed on 
fresh-isolated, fresh-encapsulated, and aspirated encapsulated 
islets using low- (1.67 mM) and high-glucose (16.7 mM) solu-
tions. Approximately the same number (10–20) of islets were 
incubated for 60 and 90 minutes in low and high glucose, 
respectively, and the supernatants were collected and stored 
for subsequent C-peptide analysis via ELISA following the 
manufacturer’s protocol.
RESULTS
Preimplantation Characteristics of Components and 
Microbeads
Alginate Immunogenicity 
Immunogenic potential of the alginate included the assess-
ment of endotoxin levels with the EndoSafe assay and 
ELISA-based quantitation of other immunocontaminants 
and a cell-based assay to gauge pathogen-associated molecu-
lar pattern–based immunostimulatory potential. Testing in a 
THP1-XBlue-MD2-CD14 cell line showed that the alginate 
increased activation of NF-κB/AP-1 when compared with the 
control sample (Figure S1A, SDC, http://links.lww.com/TXD/
A205). Additional testing of the biological activity of the 
peptidoglycan with HEK-Blue cell lines overexpressing Toll-
like receptor-2 (TLR-2) showed that the alginate had TLR2-
stimulating effects (Figure S1B, SDC, http://links.lww.com/
TXD/A205). Finally, the quantitative ELISA for lipopolysac-
charide in the starting alginate material was under the limit of 
detection (4.1 ng/mL), and the levels for the alginate postfil-
tration were below 1 EU/mL. Levels of lipoteichoic acid and 
flagellin were not detectable (Figure S1C, SDC, http://links.
lww.com/TXD/A205). However, the peptidoglycan level was 
0.4 ng/mL and evaluated as being higher than the desirable 
limit of <0.1 ng/mL. Overall, the alginate to be used in the 
study had a relatively low immunogenicity profile but con-
tained immunocontaminants with the potential to stimulate 
innate immune responses.
CXCL12 Purity and Potency
Two different sources of recombinant human CXCL12 
were analyzed for potential use in this study: CXCL12 pro-
duced by Peprotech, Inc. (Rocky Hill, New Jersey) using an E 
coli expression system and CXCL12 from Almac (Craigavon, 
United Kingdom), which is produced using solid-state peptide 
synthesis techniques (Results S5, SDC, http://links.lww.com/
TXD/A205).
Empty Microbead Morphology
Two batches of approximately 400 000 empty alginate 
microbeads each were produced, 1 with and 1 without 
CXCL12. The size and roundness of these microbeads were 
assessed. The resulting size and shape of the microbeads 
did not appear to be affected by the presence of CXCL12. 
Microbeads without CXCL12 (sample A) had a mean diam-
eter of 426.55 ± 27.36 μm with a circularity of 0.78 ± 0.13, 
while microbeads with CXCL12 (sample B) had a mean diam-
eter of 428.27 ± 37.23 μm with a circularity of 0.80 ± 0.12 
(Figure 1A and B).
Preimplantation porosity studies on these microbeads 
using a dextran diffusion analysis after 30 minutes dem-
onstrated an increase in fluorescence intensity for all 3 
preconjugated dextrans. Penetration rates were 90% 
CXCL12 (−) and 95% CXCL12 (+) for the 10 kDa dextran, 
55% for both samples with 150 kDa dextran, and 30% for 
both samples with the 500 kDa dextran (Figure S2A, SDC, 
http://links.lww.com/TXD/A205). At the 1-month assess-
ment, 30-minute microbead permeability declined signifi-
cantly for the 10 kDa dextran (~70%), while the 150 kDa 
dextrans declined ~20% and the 500 kDa declined ~40% 
(Figure S2B, SDC, http://links.lww.com/TXD/A205).
Autologous Islet Microbead Production, Size, and 
Shape
For the production of autologous islet microbeads, to 
minimize the number of nonislet-containing microbeads, 
the volume of alginate solution applied was based on the 
volume of provided islets. About 40 000 islet equivalents 
were isolated from the hemipancreatectomy on the first 
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NHP (Results S6; Figure S3A–C, SDC, http://links.lww.
com/TXD/A205). For the production of autologous islet 
microbeads from the second NHP hemipancreatectomy, we 
utilized an airflow encapsulation process with a 400-μm air-
dripping nozzle, and the encapsulator settings were opti-
mized for this process (Results S6; Figure S3G–S3I, SDC, 
http://links.lww.com/TXD/A205).
Postimplantation Effects of Empty Microbead Implants
Overall Animal Health During Study 
Both NHPs receiving the empty microbead implants recov-
ered quickly from surgery and appeared healthy during the entire 
period of the study. Neither NHP had any significant changes in 
behavior, appetite, or weight, nor were there any abnormal com-
plete blood count with differential or serum chemistry results 
over the 6 months of the study (data not shown).
FIGURE 1. Images of the original empty microbeads preimplantation and appearance of retrieved microbeads postexplant, together with the 
gross surgical appearance at the specific time points. Set of the preimplantation microbeads used for the NHP implants are shown (A) without 
CXCL12 (−) and (B) with CXCL12 (+). Size and shape of the microbeads were very similar between the CXCL12 (−) and CXCL12 (+) samples, 
magnification ×4. Images of the microbeads postexplant at day 30 are shown (C) without CXCL12 (−) and (D) with CXCL12 (+). Similar images 
shown in A–B and E–F were used by University of California Irvine and their software program for the microbeads size and shape evaluation. 
Explanted microbeads at day 90 are shown (G) without CXCL12 (−) and (H) with CXCL12 (+). Microbeads measured 500–530 μm in diameter, 
magnification ×10. Explanted microbeads at day 180 are shown (I) without CXCL12 (−) and (J) with CXCL12 (+). Microbeads explanted from the 
CXCL12 (−) NHP were in the range of 480 ± 43 μm, and some microbeads appear to have a pigmentation with changed surface but without 
obvious cell infiltration. Microbeads from the CXCL12 (+) NHP were in the range of 485 ± 12 μm, magnification ×10. Images from the surgical 
appearance of microbeads (shown with arrows) at days 30, 90, and 180 demonstrate visible numerous concentrations of microbeads within 
the peritoneal cavity of NHPs (K) without CXCL12 (−) and (L) with CXCL12 (+) at day 30. M, Image of the omental tissue with CXCL12 (−) 
NHP demonstrates the cluster of microbeads (N) with CXCL12 (+) NHP at day 90. Microscopic images of the tissues with embedded empty 
microbeads from the CXCL12 (−) explant at day 180 are shown with arrows in O–P, demonstrating the “vesicle-like” pouch around the single 
microbeads with a visible vascularization, and tissues with embedded empty microbeads from the CXCL12 (+) are seen in Q and R. NHP, 
nonhuman primate.
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Changes to Free Microbeads 
At the 1-month assessment, we instilled a single 100-mL 
normal saline lavage in each NHP and aspirated a roughly 
equal amount of microbeads from each animal, representing 
53%–56% of the original implant volume. During the proce-
dure, a sample of these aspirated microbeads was examined 
using phase contrast microscopy. These microbeads appeared 
to have a normal morphology and appearance without sig-
nificant aggregation and were clearly transilluminable without 
evident cellular infiltrate on the surface of the microbeads. A 
second sample of the microbeads from each NHP were imaged 
and measured several hours after the removal (Figure 1C and 
D). These showed an increase in median diameter compared 
with the size measured before implantation. CXLC12 (−) 
microbeads had increased in size by 33.8% (median = 570 μm), 
while CXCL12 (+) had increased by 44.3% (median = 609 
μm). Images of these microbeads were also sent to University 
of California Irvine for assessment (Figure 1E and F). As these 
samples had been stored in the lavage solution for several hours 
before these measurements were taken, it is possible that the 
beads swelled in the normal saline solution. We subsequently 
washed and stored a sample of the aspirated microbeads in a 
0.9% w/v NaCl solution and imaged them again after an addi-
tional 4 weeks. At that time, the CXCL12 (+) microbeads had 
a mean diameter of 591 μm (38.2% increase in diameter over 
the implant size), showing that these microbeads had stabilized 
in a normal saline solution (data not shown).
At the 3-month evaluation, free microbeads were seen 
throughout the peritoneal cavity of both animals, and there were 
again no visible indications of embedded beads in either animal 
and in particular in the Pouch of Douglas. A single 30-mL lavage 
released a small volume of microbeads from either animal (~300 
μL of microbeads from the CXCL12 [−] implant and ~230 μL 
of microbeads from the CXCL12 [+] implant), amounting to 
only 2000–5000 microbeads in each case. Measurements were 
done on 50 microbeads using the captured images and the 
ImageJ software. Microbeads without CXCL12 (−) had a mean 
diameter of 499.67 ± 17.98 μm with a circularity of 0.9598, 
while microbeads with CXCL12 (+) had a mean diameter of 
509.16±14.56 μm with a circularity of 0.9698. There was no sig-
nificant difference in the size between these 2 samples of micro-
beads. Also, the number of recovered microbeads from lavage 
was small; therefore, we did not provide a graph representing 
these measurements. Because many microbeads were visible in 
the peritoneum, it is not clear why the number of microbeads 
recovered from the lavage was small. This could have been due 
to the use of a smaller volume of IP lavage (30 mL) and the 
minimal effort taken to remove beads from the peritoneum to 
minimize the disruption of the tissues, or due to more significant 
adherence of the beads on the surface of the peritoneal tissue. 
Microbeads recovered from the CXCL12 (−) implant showed 
some signs of degradation as indicated by a loss of circularity 
and change in the shape (Figure 1G), while microbeads from the 
CXCL12 (+) implant were without damage and remained more 
circular (Figure 1H).
At the 6-month time point, about 500 μL of free micro-
beads was recovered from the peritoneal lavage of the 
CXCL12 (−) animal and ~200 μL from the CXCL12 (+) 
animal. The CXCL12 (−) microbeads were more variable in 
size (491.55  ±  45.9 μm) than the CXCL12 (+) microbeads 
(501.81 ± 22.69 μm); a minority of CXCL12 (−) microbeads 
showed change in transparency (7.55%), and 1.89% showed 
cellularization on the surface. In contrast, the CXCL12 (+) 
microbeads were round, relatively uniform in size, clear, and 
not cellularized. Samples of each microbead were first imaged 
(Figure 1I and J) and then placed in a culture media to observe 
the possible additional changes during an extended period of 
time. It is very likely that microbeads picked up a pigment in 
the animals, perhaps related to a foreign body reaction. The 
CXCL12 (−) samples became discolored even more during 
the period of 7–10 days, while the CXCL12 (+) microbeads 
remained transparent and translucent without pigmentation 
(data not shown). Again, microbeads were found throughout 
the peritoneal cavity and did not accumulate or aggregate to 
any detectable extent in the Pouch of Douglas.
Changes to Peritoneum 
At the 1-month surgical evaluation, visual inspection did 
not show any intra-abdominal inflammation or physical evi-
dence of adhesions in either NHP (Figure 1K and L). In both 
animals, the microbeads appeared distributed throughout 
the peritoneum and were lightly adherent to tissue surfaces 
with no sign of concentration in the pelvic floor. No obvious 
embedding of microbeads within in the IP tissue was observed. 
At the 3-month assessment, the NHP receiving the CXCL12 
(−) implant showed some evidence of peritoneal adhesions 
and patchy fibrosis, while the NHP receiving the CXCL12 
(+) had no evidence of any IP reaction (Figure 1M and N). 
At the 6-month assessment point, differences in peritoneal 
appearance between the 2 animals were more accentuated. In 
the NHP receiving the CXCL12 (−) implant, additional intra-
abdominal adhesions and a patchy fibrosis on scattered sur-
faces of the peritoneum  were seen. At this point, embedded 
microbeads now appeared for the most part to be surrounded 
by mesothelial cells as seen in Figure 1O and P. In comparison, 
the peritoneum of the animal receiving CXCL12 (+) implants 
looked unchanged from before implantation with no indica-
tions of any adhesions or fibrosis (Figure 1Q and R).
Changes to Embedded Microbeads 
At the 1-month peritoneal inspection, a number of loca-
tions in both animals were noted that had what appeared to 
be embedded microbeads, and biopsies were taken at these 
locations (Results S7, SDC, http://links.lww.com/TXD/A205; 
Figure  2A–H). At the 3-month evaluation, several biopsies 
were taken from random locations, as no embedded beads 
were evident from a visual inspection (Figure  2I–O). At 6 
months, a few samples of each microbead were fixed and pre-
pared for hematoxylin and eosin staining (Results S7, SDC, 
http://links.lww.com/TXD/A205; Figure  2L and P). There 
were no significant signs of cellularization or fibrosis.
Changes in Plasma and Peritoneal Cytokine and 
Chemokine Levels 
In blood samples drawn both before microbead implanta-
tion and at postimplant weeks 1, 2, 3, 4, 13, and 26, only 4 
cytokines were measurable in the plasma: interleukin-4 (IL-4), 
IL-17a, IL-23, and tumor necrosis factor-α. The NHP receiv-
ing the CXCL12 (−) implant appeared to have a higher basal 
activation state for cytokine levels than the NHP with the 
CXCL12 (+) implant. Both NHPs showed a transient spike 
in circulating IL-23 between the second and third weeks after 
implantation. No other changes in cytokine levels compared 
to baseline measurements either in plasma or in IP aspirate 
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samples (Figure 3A) were seen. The 3- and 6-month plasma 
and IP aspirate samples from both NHPs showed minimal 
cytokine changes for granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), IL-18, IL-5, and IL-6 from baseline 
preimplantation levels (Figure  3B and C). There is a possi-
bility that alginate microbeads being a foreign biological 
source material to the innate immune system could trigger 
this cytokine increase. IL-5 is known also to be coexpressed 
with GM-CSF, which was also elevated in our study. IL-6 can 
be secreted by macrophages as a proinflammatory cytokine in 
response to specific microbial molecules.
Plasma and Lavage CXCL12 Levels Postmicrobead 
Implantation 
To evaluate the possible changes in circulating levels of 
CXCL12 from the implants, we evaluated preimplant sam-
ples from 13 different healthy control cynomolgus macaques. 
The plasma level of CXCL12 ranged between 340 and 620 
pg/mL, with an average value of 480.53 pg/mL. Serum lev-
els of CXCL12 in the 2 NHPs receiving empty microbeads 
on the day of implantation were 500.01 ± 69.79 pg/mL for 
the CXCL12 (−) NHP and 666.13 ± 165.14 pg/mL for the 
CXCL12 (+) NHP. There was a statistically significant effect 
noticed in CXCL12 level between 2 NHPs for days 9 and 14 
(Figure 3D). We also measured CXCL12 from the peritoneal 
lavage, normalizing results with dilution factors. At 1 month, 
the CXCL12 (+) lavage sample showed about a 3-fold higher 
level of CXCL12 than the CXCL12 (−) lavage sample (Figure 3E). 
This difference was not evident by the 3-month evaluation, as the 
levels in the CXCL12 (−) NHP increased significantly by that 
point. At the 6-month point, the concentration of CXCL12 from 
the lavage of the CXCL12 (+) animal was about half of the con-
centration in CXCL12 (−) animal at day 98.
Changes in Populations of PBMCs 
A review of changes in population of PBMCs is shown in 
Results S8 and Figure S4 (SDC, http://links.lww.com/TXD/
A205).
Postimplantation Effects of Autologous Islet 
Microbead Implants
Overall Animal Health During Study 
Both NHPs receiving the microbead implants recovered 
quickly from surgery (hemipancreatectomy and autologous islet 
transplantation) and appeared healthy during the entire period 
of the study (Results S9, SDC, http://links.lww.com/TXD/A205).
FIGURE 2. Histopathology of the explanted empty microbeads without CXCL12 (−) and with CXCL12 (+) from days 30 to 180. Samples of 
the microbeads at day 30 are shown in A–H. A, Tissues with embedded microbeads explanted from the NHP without CXCL12 (−). B, Fibrosis 
of the tissues with microbeads from the CXCL12 (−) NHP. C, Microbead sample found in the aspirate debris. D, IHC staining of the tissues from 
CXCL12 (−) NHP, stained with antifibroblast activation protein alpha (brown color) and with antimacrophage (red color), magnification ×10. E–G, 
Tissues with embedded microbeads explanted from the NHP with CXCL12 (+). H, IHC staining of the tissues from CXCL12 (+) NHP, with same 
staining as for the CXCL12 (−) NHP, magnification ×10. Images showing the explanted tissues (I) and free microbeads (J and K) from CXCL12 
(−) NHP and explanted tissues (M) and free microbeads (N and O) from CXCL12 (+) NHP, respectively, at day 90. As it can be seen in the panels 
with free microbeads, there were no visible cell attachments or fibrosis present in these samples, magnification ×4 and ×20. H&E staining of 
the explanted tissues from CXCL12 (−) NHP with embedded microbeads at day 180 is shown in image (L) and from CXCL12 (+) NHP shown in 
image (P), magnification ×10. H&E, hematoxylin and eosin; IHC, immunohistochemistry; NHP, nonhuman primate.
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Changes to Free Microbeads Containing Autologous 
Islets Posttransplantation 
In contrast to the large number of microbeads recovered from 
the 2 NHPs receiving a empty microbead implant, a single peri-
toneal lavage of 50 mL in the first animal at 1 month resulted 
in the recovery of only about 200 microbeads. Microscopic 
examination of these recovered microbeads showed that 1%–
2% were damaged by the aspiration of the lavage. Nevertheless, 
these recovered microbeads were transparent, retained a smooth 
and regular morphology, showed no sign of cell infiltration or 
FIGURE 3. Cytokine and CXCL12 concentrations from the CXCL12 (−) and CXCL12 (+) empty microbeads study. Cytokine concentrations 
from the samples of NHP plasma are shown in A and B, while aspirate samples are shown in C. A, Measurable levels of 4 cytokines (IL-17a, 
IL-23, IL-4, and tumor necrosis factor-α) in both NHPs at days 0–28, and it appeared that NHP with CXCL12 (−) had a higher level of activation 
state for these cytokines when compared with the baseline levels. Two-way ANOVA analysis demonstrated for IL-23 significant P values (***P < 
0.001) for prebleed vs day 9, day 9 vs day 21, and day 9 vs day 14. B and C, For days 90, 97, 136, and 180, inflammatory cytokine changes were 
observed for both CXCL12 (−) and CXCL12 (+) microbeads, both in plasma and intraperitoneal (IP) aspirate. Standard curves for each cytokine 
were used to extrapolate the concentrations from the FI-background data. Significant P values were observed for GM-CSF (***P < 0.001, *P < 
0.05), IL-18 (**P < 0.01), IL-5 (***P < 0.001), and IL-6 (*P < 0.05). The CXCL12 concentrations are shown in D and E. D, The comparison between 
the CXCL12 (−) and CXCL12 (+) plasma concentrations from days 0 to 180 postimplant. **P < 0.01 for day 9, and ***P < 0.001 for day 14. E, 
The aspirate concentrations of CXCL12. The results of 28 days were showing a 3-fold increase in chemokine in the CXCL12 (+) animal, with a 
**P value < 0.05. The 98-day aspirate samples (*) being stored at −80oC, were assayed twice, and the results demonstrated a decrease in the 
concentration over time. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; NHP, nonhuman primate.
FIGURE 4. Histopathology on explanted free and embedded microbeads from autologous implants at days 30 and 180. A–F, H&E staining 
of the recovered free microbeads from the first autograft at day 30. Visible nucleated islets and also some denucleated clusters. E, Visible 
damage from the recovery or staining process. G and H, H&E staining of the tissue-embedded microbeads from the first autograft at day 
30. Image showed no cellularization around the capsule but some denucleation of the islets. I–L, H&E staining of the recovered embedded 
microbeads from the first autograft at day 180. Visible presence of more denucleated islet clusters, but still without significant cellularization. 
M and N, Histology of the embedded microbeads from the second autograft at day 30. Images showing no cellularization around the capsules. 
O and P, IHC staining of the embedded microbeads from the second autograft at day 30. Tissues around microbeads stained with antifibroblast 
demonstrate the presence of the cells and damage to the microbead structure. Q and R, H&E staining of the recovered embedded microbeads 
from the second autograft at day 180. There were no detectable islet clusters in these microbead samples. H&E, hematoxylin and eosin; IHC, 
immunohistochemistry.
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fibrosis, and appeared to contain intact islets. After recovery, 
the mean diameter of the microbeads had increased about 28% 
(1542 ± 217 μm) compared with the preimplant diameter of 
1207±164 μm (Figure S3D, SDC, http://links.lww.com/TXD/
A205). This increase in size might be caused by prolonged stor-
age in the normal saline used for lavage.
Hematoxylin and eosin staining of these recovered free 
microbeads showed visible nucleated islets (Figure 4A–F). A 
subsequent assessment at 6 months resulted in the retrieval of 
only few free microbeads (n = ~500), all of which appeared to 
be cellularized (data not shown).
Functional Assessment of Retrieved Encapsulated 
Autologous Islets 
We performed 1- and 24-hour insulin release tests on 8 
microbeads, which contained a total of 48 islets (~6 islets 
per microbead). Insulin release at 1 and 24 hours was 0.46 
and 1.17 pM, respectively, per islet, which was dramatically 
reduced from the amounts of insulin released by encapsulated 
autologous islets before transplant (447.78 and 1689.58 pM, 
respectively). We note that before these tests the microbeads 
had been stored for 3 hours at 4°C in the normal saline-con-
taining lavage fluid that was aspirated from the peritoneum 
along with the microbeads. The prolonged storage of the islets 
in this fluid may have imposed additional hypoxic stress that 
affected the levels of insulin release from the encapsulated 
islets.
In the second animal, at the 1-month assessment only about 
100 microbeads were recovered after a 100-mL lavage. These 
recovered microbeads had increased in diameter by about 
30% (870 ± 69 μm) and retained a high degree of round-
ness (0.964%) (Figure S3J, SDC, http://links.lww.com/TXD/
A205). These microbeads showed evidence of intact islets, 
although both the number and size of islets appeared to have 
decreased significantly (~60%–80%) compared with preim-
plantation. By day 180, no free microbeads could be retrieved 
from the recipient.
Changes to Peritoneum 
At the 1-month postimplant evaluation, the peritoneal cav-
ity of the first autologous islet recipient appeared normal and 
healthy; islet-containing microbeads were clearly visible on 
the peritoneal tissues (Figure S3E  and  F, SDC, http://links.
lww.com/TXD/A205). Microbeads were found throughout 
the peritoneal cavity and similar to previously did not accu-
mulate or aggregate together in the Pouch of Douglas. The 
situation with the second animal was quite different. At the 
1-month assessment, the NHP had obvious indications of 
fat-necrotizing pancreatitis secondary to the hemipancreatec-
tomy procedure; this was more visible at the 6-month biopsy 
(Figure S3K–S3L, SDC, http://links.lww.com/TXD/A205). 
This complication of surgery negatively affected the condition 
of the microbeads in the peritoneum, as discussed below.
Changes to Embedded Microbeads 
Tissue histology showed similar results to the visual micro-
scopic inspection; there was no evidence of cellularization or 
fibrosis on any of the microbeads (Figure 4G and H). Islets 
stained positively in some of the microbeads. Many islets 
appeared to contain an extensive number of denucleated cells. 
In the first autologous islet microbead recipient, tissue biop-
sies at 6 months showed the presence of cellularized and likely 
fibrosed microbeads with few islets that, when present, were 
mostly necrotic (Figure 4I–L).
FIGURE 5. Cytokine and CXCL12 concentrations from the autograft microbeads study. A–C, Plasma and aspirate cytokine concentrations 
from the first and second NHP autografts, days 0–30. The levels of GM-CSF, IL-18, IL-5, and IL-6 increased about 1.5–2× for both autografts 
when compared with the baseline levels. Two-way ANOVA analysis demonstrated various significant P values for GM-CSF, IL-18, IL5, and IL-6 
when comparing plasma from different time points (A and B) and aspirate for 2 NHPs (C). D and E, Plasma and aspirate concentrations of the 
CXCL12 in NHPs, days 0–180. D, There was a statistically significant change in the plasma CXCL12 concentrations between 2 animals for days 
0, 14, and 21. E, The NHP aspirate concentrations of CXCL12 demonstrated significant change for day 30. Day 30 aspirate sample from the 
first NHP was assayed twice (*), and the result did not demonstrate a significant decrease in the concentration over time as compared with the 
blank microbeads samples. There was a much lower concentration of CXCL12 at the 180-day time point. GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IL, interleukin; NHP, nonhuman primate.
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A number of biopsies were also taken from the second 
NHP at the 1-month evaluation. Histology of the biopsied 
tissues demonstrated clinical evidence of fat necrosis with 
accompanying IP inflammation related to the pancreati-
tis (Figure  4M  and  N). Tissues stained with anti-fibroblast 
antibodies (Figure 4O and P) confirmed the presence of the 
inflammatory process. Due to the fact that all embedded 
microbeads were cellularized and fibrosed, we did not per-
form additional biopsies on the second NHP at the 3-month 
evaluations. Tissues at the 6-month evaluation where embed-
ded beads were found showed extensive cellularization with 
fibrosis, (Figure 4Q and R).
Changes in Plasma and Peritoneal Cytokine and 
Chemokine Levels 
In comparison to the plasma samples from the NHPs 
receiving empty microbeads, here up to 9 cytokines showed 
detectable levels over the course of the study. GM-CSF, 
IL-18, IL-5, and IL-6 showed significant variation in con-
centration between different time points for both animals 
(Figure  5A  and  B). IL-5 and IL-6 increases seen here were 
thought to be secondary to the effect of pancreatitis in the 
second autograft animal. IL-5 in Th2 cells is also coexpressed 
with GM-CSF, which was also elevated in our study. IL-6 acts 
as a proinflammatory cytokine and can be secreted by mac-
rophages in response to specific microbial molecules referred 
to as pathogen-associated molecular patterns. There is a pos-
sibility that alginate microbeads being a foreign biological 
source material to the innate immune system could trigger 
this cytokine increase. Similar observation was noticed for the 
aspirate samples with significant variation between animals, 
shown in Figure 5C. The CXCL12 plasma level demonstrated 
significant change between 2 animals for days 0, 14, and 21, 
while the aspirate CXCL12 level change was significant at 
day 30 (Results S10, SDC, http://links.lww.com/TXD/A205; 
Figure 5D and E). Samples of aspirate were not collected for 
the second autograft for day 180.
Changes in Populations of PBMCs 
A review of changes in population of PBMCs is shown in 
Results S11 and Figures S5 and 6 (SDC, http://links.lww.com/
TXD/A205).
DISCUSSION
This study set out to explore in a stepwise manner whether 
data generated in mice regarding the immune isolating 
functions of CXCL12 in the context of islet microencapsu-
lation could be reproduced in a small number of NHPs—
commencing with the initial study of IP implantation of 
alginate microbeads with and without CXCL12 and subse-
quently the IP transplantation of alginate microbeads contain-
ing autologous islets with CXCL12. This includes the caveat 
that alginate beads were made with ultrapure alginate that 
was shown to have very low levels of endotoxin and very low 
levels of other immune contaminants.
Alginate is known to contain several key immunocon-
taminants that can provoke innate immune responses, includ-
ing lipopolysaccharides, peptidoglycans, lipoteichoic acid, 
and flagellin.29,32 We demonstrated that while the alginate 
used in this study was relatively low in lipopolysaccharides, 
lipoteichoic acid, and flagellin, the levels of peptidoglycan 
were about 5 times what would be considered an acceptable 
limit. The alginate showed the ability to activate both THP-1 
cells and HEK-Blue cell lines overexpressing TLR-2 in an 
immunostimulation assay. Evaluation of the other component 
of the microbeads, recombinant human CXCL12, showed a 
purity level of above 92% and an endotoxin level below 1 
EU/mg protein. We demonstrated that the additional raw and 
intermediate materials used in the manufacture of the alginate 
microbeads also had endotoxin levels below 1 EU/mg or 1 
EU/mL. The final test product was therefore highly pure but 
still had the potential to elicit an immune response against 
the alginate, making it useful for evaluating the impact of 
CXCL12 over a prolonged period. Many studies have shown 
the importance of minimizing immune contaminants from 
alginate to reduce the induction of innate immune responses 
against implanted microbeads or microcapsules.32,33
In the context of empty microbeads, and in an “n-of-1” 
-type study, we demonstrated that CXCL12 could mitigate 
against the adhesion and elements of the foreign body reac-
tion to microbeads locally with regard to the cellularization 
of beads that reiterated what had been seen in mice.34 In addi-
tion, there was an unexpected impact of CXCL12 on post-
implantation intra-abdominal adhesion formation and overall 
peritoneal reaction to the implant in comparison to empty 
alginate microbeads without CXCL12.
Over a 6-month period, free microbeads with CXCL12 
remained in pristine condition compared with the deteriora-
tion that progressively occurred in the CXCL12 (−) micro-
beads. This phenomenon is interesting in part because it is 
not likely that the original CXCL12 is retained within the 
microbead for this amount of time. In a previous study, we 
estimated that supraclinical levels of CXCL12 remain in 
the microbeads for a matter of weeks.5 In a different study, 
Duncanson and Sambanis35 suggest that the retention time 
of significant concentrations of CXCL12 is a matter of days. 
In any case, a shorter-term release of CXCL12 from alginate 
microbeads appears to result in long-term control of the local 
and systemic inflammatory response to microbeads in the IP 
cavity. The phenomenon we saw with these empty beads, even 
those without CXCL12, was significantly different than the 
rapid overgrowth and tissue embedding described by oth-
ers for microsphere implantations in NHPs.36,37 These teams 
indicated that alginate microbeads at approximately the size 
we used, when introduced intraperitoneally into NHPs, were 
embedded into the omental tissue and fat by 7–14 days. In 
our case, most implanted microbeads were still free of cellular 
overgrowth at 1 month. There are few other published com-
parators for this effect, as most investigators have used mul-
tishell microcapsules with polylysine or polyornithine, which, 
if optimized, are not very adherent.38-40
This unexpected long-term effect of CXCL12 appears to go 
beyond the preservation of the microbeads themselves, as the 
CXCL12 (+) microbeads appeared to reduce the number of 
adhesions in the peritoneum and the development of fibrosis 
in the tissues. Again, few differences were noted between the 
2 animals at the 1-month assessment point. However, at 3 and 
6 months, the peritoneum of the NHP receiving CXCL12 (−) 
microbeads showed increasing evidence of patchy fibrosis and 
development of adhesions. These were absent in the peritoneum 
of the NHP receiving the CXCL12 (+) microbeads. It is pos-
sible that these differences were related to an increase in the 
peritoneal concentration of CXCL12 in the NHP receiving the 
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CXCL12 (+) microbeads, or due to the increase in foreign body 
responses in the NHP receiving the CXCL12 (−) microbeads, or 
a combination of both. While no statistically significant circulat-
ing levels of CXCL12 were seen in either animal, there appeared 
to be about a 3 times greater level of CXCL12 in the lavage fluid 
of the CXCL12 (+) microbead recipient at 1 month than the 
CXCL12 (−) microbead recipient. It is hard to draw firm conclu-
sions from this 1 set of samples, especially because there are no 
baseline levels of CXCL12 in the peritoneum to use as a com-
parison. However, the time at which this peak level occurred in 
the peritoneal lavage certainly matched the time period of sig-
nificant release for the CXCL12 from the alginate microbeads.
While the empty microbead implantation study shows the 
potential for encapsulated CXCL12 to enhance the isolation 
of microbeads from the inflammatory and innate immune 
response, the study of alginate microencapsulated autologous 
islets in NHPs raised different issues. In the first instance, it is 
clear that the microencapsulated autologous islet transplanta-
tion model is technical, complex, and challenging. First, the 
partial pancreatectomy has a complication rate in NHPs, 
including the development of acute pancreatitis associated 
with the residual pancreas, which was revealed clinically by 
evidence of IP inflammation, peripancreatic fat necrosis, and 
slight elevations in pancreatic markers in the second NHP. 
Second, partial pancreatectomy, islet isolation, microencapsu-
lation, and implantation are mandated to be completed on the 
same day in the same NHP. This means that the quality con-
trol on islet preparations, microencapsulation, and implanta-
tion must consequently occur with the NHP maintained under 
a prolonged (6–8 hours) period of anesthesia while all relevant 
procedures are completed. Finally, and most significantly, the 
microencapsulated autologous islet implantation procedure 
involves the placement of the microbeads into an inflamed and 
postsurgical site—namely, the IP cavity of an NHP postpar-
tial pancreatectomy. This sets a confoundingly high bar for 
the CXCL12 effect on the inflammatory and immune isolation 
of the microbead graft to reach. We suggest that the second 
NHP demonstrated all of these negative impacts on microbead 
transplantation because of the evident postpartial pancreatec-
tomy pancreatitis. Interestingly, there was clear evidence that 
microbeads remained transilluminable without cellular encase-
ment up to 3 months in the first NHP, but it was clear that the 
autologous islets themselves showed greatly reduced function 
at both 3 and 6 months postimplantation. Therefore, while in 
concept autologous islet transplantation in the NHP would 
remove the variable of anti-islet immune responses from the 
model, in execution it is likely far more invasive and induces 
a significant postsurgical inflammatory response and adds a 
potentially significant confounding factor in the studies.
This study may also demonstrate the limits to the ability of 
CXCL12 to aid adult autologous islets surviving nonimmune 
environmental changes. After implantation, islets are vulner-
able to stresses such as hypoxia,41-45 local cytokine release,46,47 
and the effects of hyperglycemia.48,49 These can cause loss of 
islet function and death, even without an innate or adaptive 
immune attack. Here, both sets of autologous islet implants 
appear to have been affected by postimplant stressors. In the 
absence of indications of cellularization, fibrosis, or innate 
immune response to the free microbeads, the encapsulated islets 
showed a significant decrease in the number of visible islets, islet 
size, and insulin release. Histology indicated that most intact 
islet clusters were partially or largely anucleated. In the first 
autologous graft recipient, this outcome might have been in 
part due to the suboptimal encapsulation that resulted in 4–5 
islets per bead and a larger bead size, both of which can result 
in hypoxic states.41,50,51 While a recent study has suggested that 
microbead size may not have a negative impact on islet sur-
vival,37 a number of other studies suggest that microbeads are 
most effective when the maximum distance between the islet 
and the bead surface is <150 μm and that larger microbeads 
present challenges to islet viability.44,52-56 As a result, multiple 
islets within a larger microbead would have been competing for 
nutrients and oxygen where the microbeads did not have direct 
vascular access and where oxygen tensions are relatively low.44,57
One significant unanswered issue from this study is related to 
the long-term fate of the majority of implanted alginate micro-
beads. Historically, there have been concerns about the stabil-
ity of alginate microbeads crosslinked with calcium ions. Some 
studies suggest that when calcium alone is used as a crosslinking 
ion, it can be replaced over time by sodium ions, resulting in the 
dissolution of the microbeads.58 Consequently, some investiga-
tors have utilized barium or strontium alone or in combination 
with calcium as crosslinking ions.59 Evidence from this study on 
the long-term stability of these calcium-crosslinked microbeads 
is ambiguous. First, while the alginate microbeads appeared to 
swell after placement in the peritoneum by 28%–44%, reflecting 
the presence of sodium ions in the peritoneal fluid and in the lav-
age solution, this size change remained constant over a period of 
months and therefore may not signal instability for the microbe-
ads. In both animals, some free microbeads were recoverable up 
through the 6-month period. At this assessment, the CXCL12 (−) 
microbeads showed more variation in size and shape that could 
suggest instability of the beads. However, there were very little 
indications of instability in the CXCL12 (+) sample, where free 
microbeads appeared as pristine as the day they were implanted. 
It may be that the use of CXCL12 in the alginate promotes sta-
bility of the bead. CXCL12 can ionically bind to guluronate units 
within alginate,60 and this ionic binding may serve to enhance the 
long-term stability of calcium-crosslinked alginate microbeads.
Together, the data from this n-of-1-type study examining 
the function of empty and autologous islet microbead studies 
in NHPs support the next step in our project, which includes 
alloislet and xenoislet transplantation into nondiabetic NHPs. 
These results provide support for the utility of CXCL12 in 
immunomodulation for these types of alginate microbeads, 
highlight the continued importance of the high purity of algi-
nate and other microbead components, and help to identify 
key parameters to address any hurdles to overcome in future 
studies. These most notably include the need for optimization 
and standardization of the islet and islet microbead prepara-
tion process and the challenges of sustaining islet functional 
survival in the face of nonimmune stressors including the 
inflammatory response to the microbeads and hypoxia.
In addition, the study demonstrates that studies of this type 
involving very small numbers of NHPs can reveal important 
technical and scientific issues that need to be addressed in 
subsequent appropriately statistically powered studies as this 
approach to islet transplantation is developed toward first in 
human studies.
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